Full-Time
Downstream Marketing Manager
Confirmed live in the last 24 hours
Synchron
51-200 employees
Develops brain-computer interface technology for patients
Compensation Overview
$130k - $145kAnnually
Senior
Remote in USA
Remote work will be considered; ideally located in New York City with ability to travel into Brooklyn.
You match the following Synchron's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Bachelor’s degree in Marketing, Business Administration, Neuroscience, Biomedical Engineering, or related fields
- Minimum of 5 years of downstream marketing or product marketing experience in medical devices, biotech, or neurotechnology industries, with a focus on early-stage or pre-revenue companies
- Proven expertise in managing Salesforce or similar CRM platforms for stakeholder engagement
- Exceptional communication skills, with the ability to translate complex technical concepts into compelling narratives
- Strategic mindset with the ability to execute in a lean, fast-paced startup environment
- Adept at building relationships with scientific and clinical communities
- Proficient in digital marketing tools, data analytics, and content management systems
- Collaborate with the upstream, product, and clinical teams to define unique product value propositions and refine customer journeys
- Build relationships with healthcare providers, patient advocates, and potential partners to achieve commercial goals
- Manage communications with key stakeholders, ensuring alignment with company milestones, clinical trial progress, and scientific advancements
- Implement and optimize Salesforce or similar CRM platforms to track engagement with clinicians, investors, and other stakeholders
- Develop workflows to segment audiences, automate outreach, and track outcomes to support pre-revenue growth objectives
- Collaborate with Marketing-Communication partners to develop engaging social media campaigns that further commercial goals
- Create compelling marketing assets, including scientific content, white papers, webinars, and presentations tailored to highly technical and medical audiences
- Collaborate with clinical and medical education to create clear and concise collateral to train users during clinical trials
- Oversee product positioning messaging to ensure alignment with the company’s mission and technical credibility
- Collaborate with Upstream to develop and maintain a claims matrix that will drive therapy adoption
- Collaborate with the clinical team to translate trial data into marketing and educational materials
- Define KPIs to measure the success of pre-revenue marketing and engagement initiatives
- Regularly present data-driven insights and recommendations to the commercial leadership team. Turn data into information
- Work closely with cross-functional teams, including clinical, regulatory, and R&D, to ensure marketing aligns with the company’s development milestones
- Play a key role in growing the marketing team as the company progresses toward commercialization
- Develop, manage, and execute Congress and Advocacy Organization strategies that align marketing resources to business goals
- Monitor competitive activity and develop messaging strategy to further Synchron’s leadership in the field
- Ability to achieve results by working cross-functionally and collaboratively across a matrix organization, including scoping and managing projects
- Experience in market development for disruptive technologies, particularly in regulated industries
- Strong understanding of clinical trial processes, regulatory landscapes, and commercialization pathways
Synchron develops brain-computer interface (BCI) technology that enables individuals, particularly those with severe paralysis, to control digital devices using their thoughts. Their main product involves a minimally invasive endovascular procedure for implanting the BCI, which is similar to placing stents and avoids the need for open brain surgery. This approach makes the technology safer and more accessible for patients with neurological conditions that limit their ability to communicate or move. Unlike competitors, Synchron focuses on a less invasive method of BCI implantation, which can lead to quicker recovery times and broader patient eligibility. The company's goal is to enhance patient autonomy and social connection by providing them with the ability to interact with technology through thought, ultimately transforming the landscape of medical technology for those with severe impairments.
Company Size
51-200
Company Stage
Series C
Total Funding
$130.6M
Headquarters
New York City, New York
Founded
2016
Simplify's Take
What believers are saying
- Collaboration with Nvidia enhances on-device neural processing for more efficient BCI systems.
- Integration with Amazon Alexa opens new markets for BCI technology in smart homes.
- Participation in the BMI Summit positions Synchron as a leader in neurotechnology innovation.
What critics are saying
- Competition from Blackrock Neurotech and Precision Neuroscience may impact Synchron's market share.
- Ethical concerns may arise from handling sensitive brain data with generative AI.
- Dependency on Nvidia's technology could pose risks if Nvidia faces setbacks.
What makes Synchron unique
- Synchron's BCI technology uses a minimally invasive endovascular procedure, unlike open brain surgery.
- The company integrates generative AI to enhance communication for non-verbal patients.
- Synchron's partnership with Amazon allows mind-controlled operation of smart home devices.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -21%On the 14th, Synchron unveiled a next-generation implantable BCI at the 2025 JP Morgan Healthcare Conference held in the United States, based on NVIDIA's real-time AI computing software platform 'Holoscan.'
Synchron plans to leverage Holoscan to boost on-device neural processing and develop a foundation model for brain inference.
What You Should Know:– Synchron, a company pioneering brain-computer interface (BCI) technology unveils a community registry that aims to bring together patients with motor impairments, their caregivers, and medical professionals to explore the potential of BCI in restoring lost functionality.– By uniting patients, caregivers, and medical professionals, this initiative has the potential to revolutionize the way we treat motor impairments and empower individuals to regain control of their lives.Minimally Invasive Brain InterfaceUnlike traditional BCI methods requiring open-brain surgery, Synchron’s technology utilizes a minimally invasive approach:Endovascular Implantation: The BCI device is strategically placed within a blood vessel near the brain’s motor cortex via the jugular vein.The BCI device is strategically placed within a blood vessel near the brain’s motor cortex via the jugular vein. Wireless Communication: The implanted device wirelessly transmits the user’s motor intent signals for external use.The Power of Community CollaborationThe Synchron BCI registry serves as a platform for:Patient and Caregiver Education: Providing patients and caregivers with valuable information on BCI technology and its potential applications.Providing patients and caregivers with valuable information on BCI technology and its potential applications. Clinician Engagement: Facilitating collaboration between clinicians, researchers, and developers to accelerate BCI advancements.Facilitating collaboration between clinicians, researchers, and developers to accelerate BCI advancements. Shared Experiences: Enabling patients and caregivers to connect and share their experiences with BCI technology.“BCI technology enables individuals with motor impairment to regain independence,” said David Lacomis, M.D., principal investigator and Chief of the Neuromuscular Division at UPMC and Professor of Neurology and Pathology at the University of Pittsburgh. “By controlling digital devices through one’s own thoughts, BCI offers a transformative path towards performing daily tasks with greater ease and efficiency. From communication to accessing essential services online, BCI technology represents a ground-breaking frontier for individuals and their families.”
In 2022, Team Gleason collaborated with Synchron to provide the company with feedback from the ALS community and other experts to help guide the design and development of its BCI technology.
Synchron is developing a BCI that decodes brain signals to allow people with paralysis the ability to control digital devices with their thoughts alone.
Brain computer interface (BCI) company Synchron this week announced a trial integrating its BCI technology with Amazon Alexa.
US-based brain-computer interface company, Synchron, has recently announced the integration of generative AI into its brain implant interface system, allowing people who are living with disabilities that cause them to be non-verbal to generate text on a screen faster and more easily than before.
Synchron announced today that it partnered with Nvidia to advance its brain-computer interface (BCI) technology.
Synchron launches patient registry to prepare for brain implant trial.
Leading Neuroscientists, Technologists, Regulators, and Venture Capitalists Convening in West VirginiaMORGANTOWN, W.Va., Aug. 9, 2024 /PRNewswire/ -- West Virginia University (WVU) Medicine will host an international gathering of scientists, engineers, researchers, physicians, and industry leaders at the Brain-Machine Interface (BMI) Summit this coming weekend. Organized by Dr. Peter Konrad of WVU Medicine and Dr. Jose "Pepe" Contreras-Vidal of the University of Houston, the event is a key programming component of the National Science Foundation's (NSF) Industry-University Cooperative Research Centers (IUCRC).The conference aims to advance the accessibility and sustainability of BMI technologies for patients with neurological conditions by underscoring the need for increased collaboration across industry, government, and university systems.The BMI Summit will feature presentations and panel discussions with prominent figures from the FDA, NIH, NSF, and VA, alongside industry leaders from companies including Blackrock Neurotech, Precision Neuroscience, and Synchron. Three pioneering patients – Ian Burkhardt, Nathan Copeland, and Jen French – who have been at the forefront of BMI device trials, demonstrating the transformative potential of these technologies will be sharing their crucial patient perspective for those dealing with disabling conditions like paralysis, stroke, speech loss, vision loss, pain, and brain injury."For 20 years, we've seen incredible advancements in BMI technology, but the journey from laboratory to bedside has too often been slow and fragmented," said Dr
What You Should Know:– Synchron, a leading innovator in brain-computer interface (BCI) technology, has announced a groundbreaking integration of generative AI into its BCI platform.– The integration, powered by OpenAI, empowers individuals with severe paralysis to interact with the digital world through thought-controlled texting, offering a new level of communication and independence.Unlocking Communication with ThoughtThe novel BCI chat feature leverages OpenAI’s advanced generative AI system to offer intuitive and user-friendly communication. Key features include:Automated Texting Prompts: The system suggests contextual prompts for texting and chatting, categorized by the user’s emotions. This intelligent assistance simplifies communication and reduces the cognitive burden for users.The system suggests contextual prompts for texting and chatting, categorized by the user’s emotions. This intelligent assistance simplifies communication and reduces the cognitive burden for users. Natural Conversational Flow: OpenAI’s multimodal GPT technology allows for natural and real-time interactions. This is crucial for individuals with neurological disorders who may struggle to generate complex responses that adapt to their environment.OpenAI’s multimodal GPT technology allows for natural and real-time interactions